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The project of preparing formulary lists of pharmaceutical drugs
at various levels, from formularies for particular medical organ-
izations to federal lists, has been going on in Russia for nearly 20
years. These lists are made by different expert bodies and serve a
number of functions: provide the basis for state regulation of
prices, determination and adjustment of wholesale and retail
surcharges, drug reimbursement, and state supply orders in
health care.
At present, the system of drug selection at the federal level is
the most transparent and well regulated [1–3], while that at the
level of medical organizations is the least developed. As for the
rules and procedures for making reimbursement lists at the
regional level, in practice there are no standardized requirements
or criteria for drug evaluation: the principles and rules of drug
evaluation, decision-making criteria, and requirements concern-
ing the information to be submitted vary to a considerable extent
(if such mechanisms exist at all) [4]. The need to standardize the
requirements for expert evaluation and submission of informa-
tion about the drug, the decision-making criteria, the implemen-
tation of the principles of evidence-based medicine, and clinical
and economic analysis (pharmacoeconomics), as well as the need
to make the process of decision making for the inclusion of
particular drugs in the regional reimbursement lists more trans-
parent, has led to the creation of an automated system called
“Dossier” for the preparation of formulary lists.
This system was originally created as a potential health
technology assessment (HTA) tool for compiling reimbursement
drug lists on the regional level. If and when necessary, however,
such a system can be easily adapted for the purpose of compiling
formulary lists on the federal and hospital/medical organization’s
levels.
Currently, there is no accredited ofﬁcial HTA body in Russia.
Formulary commissions working on the different levels of thehealth care system can serve as prototypes of such HTA bodies.
Uniﬁed algorithms, criteria, and decision-making rules as well as
evidence-based medicine and clinical and economic analysis
principles that were developed within the framework of the
Dossier automated system represent an important platform for
incorporating the HTA methodology in the activities of the
aforementioned expert organizations.
Dossier: An Automated System for the Preparation of
Reimbursement Lists
Dossier, an automated system for preparing reimbursement lists
(hereafter referred to as “the system”), was developed in the
Research Center for Clinical and Economic Evaluation and Phar-
macoeconomics of the N.I. Pirogov Russian National Research
Medical University in 2010. It is designed to help formulary
commissions of the ministries/departments of health in federal
subjects of Russia in their task of preparing reimbursement lists
of pharmaceuticals (formulary lists) on the regional level. The
online system Dossier allows the user to enter, update, store, and
evaluate information about the medicines when they are sub-
mitted for inclusion into reimbursement lists. The entire cycle of
evaluation is thus supported by the system, from the initial
application to the ﬁnal decision of the formulary commission to
grant or refuse inclusion of the drug in the reimbursement list.
Three basic principles were taken into account during the
development of the Dossier system: the principle of objective
evaluation, the principle of intellectual support, and the principle
of informatization, or the information technology principle.
The principle of objective evaluation presumes a multilevel
assessment of pharmaceutical drugs that includes three main
stages: technical evaluation, scientiﬁc evaluation (by nonstaff
chief specialist of the regional Department/Ministry of Health
in different ﬁelds of medicine), and the ﬁnal decision to include
(or not to include) the drug into the reimbursement list.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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application (drug dossier), which includes verifying whether
the data submitted by the applicant meet all relevant require-
ments. Scientiﬁc evaluation is the stage of assessment by a
chief specialist. This task calls for expertise in a particular
medical ﬁeld and a good working knowledge of modern thera-
pies and management of the disease in question in real-life
clinical practice and its current ﬁnancial burden. The evalua-
tion includes an analysis of data on clinical efﬁcacy and cost-
effectiveness of the drug, real-life management of patients
covered by the regional reimbursement scheme, the cost of
the new medication, and so on.
The ﬁrst two stages of the evaluation take place on the Web
page of the automated system. At the third stage, members of the
formulary commission meet and discuss the issue with chief
specialists, and after their meeting, the decision of the commis-
sion is posted on the Internet page.
The principle of intellectual support refers both to the applicant
(usually members of the pharmaceutical industry) and to health
care authorities (regional ministries or departments of health,
formulary commissions). To implement this principle, the appli-
cation form contains sections that encourage the applicant to
take a more rational approach to the task of determining
prioritized indications, target patient groups, and the requested
reimbursement. For example, the system asks to specify the
patient group, the number of patients covered by the regional
reimbursement scheme, the cost of medical treatment of the
disease in question, and the estimated cost to the budget of
purchasing the drug if it is included in the list for the prioritized
group. Thus, the applicant (when requesting that the drug be
included in the list), the chief specialist of the Department of
Health (when providing recommendations regarding the expe-
diency of adding the new medication to the reimbursement list),
and the representative of the Ministry/Department of Health
(when deciding whether to include the drug in the list) focus on
the actual costs and the actual patients who are already
reimbursed for the treatment of this particular medical condi-
tion. Thanks to this approach, it becomes possible to provide a
clear justiﬁcation of the need to include the new drug and the
additional ﬁnancial costs that it entails, or, alternatively, of the
need to reject the application. The essential considerations that
determine whether the drug will be included in the list within
the framework of the Dossier system are the following: a
reasonable (scientiﬁcally proven) reduction in costs for the
budget, an adequate (effective and economically expedient)
deployment of the available resources, and a clear recognition
of the existing situation with regards to the provision of
medications to patients covered by the regional reimbursement
scheme.
The principle of informatization presumes that the submission,
evaluation, and scientiﬁc analysis of the dossier (application for
inclusion in the list) take place online, while the wizard presents
prompts (requirements) that guide the user in the process of
ﬁlling in the blanks. Besides, informatization of the entire process
of adding a new drug to the reimbursement list makes the ﬁnal
decision more transparent because the system allows users to
track and time each stage of evaluation and decision making and
to view comments by experts. Working online makes it possible
to ensure interregional cooperation of formulary commissions,
and the involvement of experts from various ﬁelds (more than 25)
enables an interdisciplinary approach to selecting the drugs to be
included in the reimbursement lists.
At the moment of publication, the automated system con-
sisted of four independent modules, one for each of the following
regions: Moscow region, Sverdlovsk region, Khanty-Mansi auton-
omous area, and Samara region. More regional modules can be
added to the system as required.Registration and User Levels in the Dossier Automated
System
To start using the system, it is ﬁrst necessary to choose the right
region and section and to register. Depending on the accessibility
of particular databases and the procedures used for evaluating
the submitted applications and for their revision/modiﬁcation
(changing application status), there are ﬁve possible user levels:
applicant, technical expert, scientiﬁc expert, member of the
formulary commission, and regional Ministry/Department of
Health. The lowest level of access to databases of the system is
the applicant level, and the level of regional Ministry/Department
of Health is the highest.
Access to various databases of the automated system, author-
ization to edit/moderate applications (dossiers), menu types, and
other options that depend on the user level can be changed
(adjusted) depending on the needs of particular regions and
medical organizations.
Status of the Applications Stored in the Dossier Automated
System
Depending on the stage of evaluation, the application (dossier)
stored in the automated system is assigned a particular status
(moderation). The system speciﬁes by whom (the name of
applicant and expert), when (time), and how (comments on the
evaluation and its result) the application was submitted and
evaluated and at which time it was assigned a particular status.
The status of an application can be modiﬁed in the “Moderation”
section. The system supports eight different statuses, for exam-
ple, “under evaluation,” “passed” or failed” technical or scientiﬁc
evaluation, “approved” or “rejected” by the formulary commis-
sion, and others. The entire cycle of expert evaluation is thus
fully transparent, from the submission of the initial application
until the ﬁnal decision of the formulary commission.
Application Form for Inclusion in the Regional List and Its
Completion
The application (dossier) for inclusion of the drug in the regional
reimbursement list contains more than 30 sections that may be
divided into three main blocks: general information about the
medication, or the passport block (name and pharmaceutical
group of the drug, etc.); study results, or the evidence block
(results of clinical and pharmacoeconomic studies); and the
regional speciﬁcation block (the number of patients entitled to
reimbursement in the region, local cost of pharmacotherapy for
this disease, as determined by the system based on the submitted
International Statistical Classiﬁcation of Diseases, 10th Revision [ICD-
10] code, high-priority groups of patients who will be receiving
this medication, including the number of patients, the cost of
therapy, etc.) (Table 1). The application thus contains as much
information as possible not only about the drug but also about
the current situation with supply of reimbursed medications in
the region. Submitting an application for inclusion in the list and
evaluating submitted applications, applicants, chief specialists,
and members of the formulary commission together determine
the strategy of drug promotion and its potential/optimal place
(“niche”) in the system of drug reimbursement.
Now we describe in greater detail how to ﬁll out the applica-
tion and some sections that are particularly problematic in terms
of the frequency of mistakes made by the applicants. The
sections that seldom give rise to questions and mistakes are
mentioned only brieﬂy.
Sections 1 to 8, 10 to 13, and 30 may be called the “passport”
part of the application that provides a description of the drug: its
name, pharmaceutical form, pharmacotherapeutic group, group
of Anatomical Therapeutic Chemical classiﬁcation, grounds for
Table 1 – “Dossier” automated system application form: three main blocks and their 30 sections.
Passport block Evidence block Regional speciﬁcation block
1. International Nonproprietary
Name (INN)
14. Advantages of a new drug 9. Should the drug be covered from
the regional budget under the
government resolution regulating
reimbursement at the regional
level?
2. Trade name 15. Clinical efﬁcacy and safety
(clinical trials)
17. Clinical trials at the regional level or
real-practice data
3. Original/generic 15А. Level of evidence 18. Priority patients’ groups (age,
severity and duration of disease,
complications)
4. Included in other reimbursement
lists or not
16. Pharmacoeconomics (cost-
effectiveness of the drug)
19. Other indications (not for
reimbursement list)
5. Manufacturer 20. Cost of 1-y treatment
6. About the applicant 21. The number of patients entitled for
reimbursed drugs in the region
7. Pharmacotherapeutic group 22. Share and number of patients
eligible for prescribing of a new
drug
8. Anatomical Therapeutic Chemical
(ATC) code
23. Share and number of priority
patients’ groups eligible for a
new drug
10. Indications for which the drug is
reimbursed
24. Current standard treatment
practice
11. Dosage 25. Presence of drug in the Standards of
Care, Clinical Guidelines
12. Dosage forms 26. Current cost of medications for
treating of patients for whom the
proposed drug is prescribed
13. Course of treatment/lifelong
prescription
27. Exclusion of other drugs
30. References 28. Cost for inclusion of a drug into the
reimbursement list for priority
patients’ groups
29. Training of physicians
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applicant. In section 6 (“About the applicant”), it is important to
include a personal e-mail address (of the person in charge of
completing the application) without any spelling mistakes in the
address. Failure to do so will result in the applicant not being able
to stay in touch with the database and be informed about the
progress of evaluation and its results.
Section 9 asks to specify the disease (or the disease within a
particular target social category) that is the indication for pre-
scribing the drug, in accordance with Decree№ 890 of the Russian
government of July 30, 1994.
In this section, the applicant has to specify whether the drug
can be included in the regional reimbursement list for a partic-
ular social or nosological category (a particular medical condition,
independently of a social category), or both.
Section 14 of the application asks the applicant to describe the
advantages of the new drug that justify its inclusion in the
reimbursement list. The applicant should list the main features
of the medication that make it preferable to, and different from,
other medications with the same indications that are already on
the reimbursement list. Apart from clinical advantages, it is
important to specify the economic advantages of the drug in this
section (if any), as well as convenience of use (a more convenient
regimen, tablets vs. injections, etc.), good compliance with treat-
ment, inclusion in international and Russian treatment guide-
lines or standards of medical care, and so on. Any advantages ofthe drug have to be very speciﬁc (preferably numbered) and
supported by evidence from well-designed clinical and pharma-
coeconomic studies, approved standards, guidelines, and
instructions.
Section 15, “Clinical efﬁcacy and safety,” requires ﬁlling out a
separate form (abstract) describing the clinical studies that are
referred to in this section. Priority is given to systematic reviews,
meta-analyses, and randomized controlled double-blind clinical
trials. Abstracts should contain a description of study design,
duration of follow-up, number of patients included in the study,
comparators, study results, level of evidence for the efﬁcacy of
the drug, and so on.
At present, many applicants consciously (exaggerating the
quality of the study on purpose) or unconsciously (because of
technical errors or poor knowledge) make mistakes in this
section. The problem is that incorrect data that contradict the
clinical trials submitted for evaluation are entered in the form; for
example, randomization is claimed when it was not performed,
and a control group is mentioned where there was none, or the
level of evidence for drug efﬁcacy is exaggerated. The data
presented in the abstract are always compared with the actual
results of the clinical trial in the course of evaluating the
application; therefore, the expert will not be led astray by such
incorrect statements.
In section 15A, the applicant has to specify the level of
evidence proving the clinical efﬁcacy of the drug, that is, the
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A list of possible levels of evidence is given in the application.
Section 16 contains data on the cost-effectiveness of the drug.
As with clinical efﬁcacy and safety, the applicant has to ﬁll out a
separate form—an abstract of the pharmacoeconomic study. The
abstract should include a description of study design, the type of
pharmacoeconomic analysis, effectiveness criteria, costs, effec-
tiveness, cost/effectiveness ratio, etc. As in the clinical efﬁcacy
and safety section, applicants often make mistakes here or
misinterpret the results of pharmacoeconomic studies. Often,
the results of these studies do not correspond to the data
included in the abstract. Thus, costs may be incorrectly described
as direct and indirect, whereas only direct costs were considered
in the study, effectiveness criteria may be described incompletely
or incorrectly, incremental cost-effectiveness ratio may be men-
tioned while it was never calculated in the study, and so on.
In section 17, experience in the region, the applicant has to list
all clinical trials that were conducted in medical organizations of
the region for which inclusion in the reimbursement list is
considered. In practice, however, such studies are very uncom-
mon. Accordingly, the applicant will normally simply list all
medical organizations that have already used this drug. A
complete lack of experience using the drug in this particular
region or by the chief specialist may become the ground for
rejection of the application for inclusion into reimbursement
lists, even if the chief specialist provides a formal approval. There
have already been such cases.
In section 18, the applicant is asked to deﬁne prioritized
groups of patients who will receive the drug for a particular
indication(s) as far as this is possible (these are the patients who
will be particularly likely to need this medication if it is included
in the reimbursement list). Prioritized patient groups, or seg-
ments, may be deﬁned by age, severity and duration of the
disease, complications, comorbidities, and so on. This section is
completed together with a chief specialist who is a member of
the formulary commission. In practice, it may be hard for the
applicant (who is usually a representative of the pharmaceutical
company that manufactures the drug) to deﬁne the prioritized
group(s) of patients. First, the applicant is not well informed
about all the characteristics of regional reimbursed patients.
Second, the applicant’s a priori position is that all patients to
whom such treatment is indicated and who are entitled to
reimbursement should be given this particular drug. This reason-
ing, however, fails to take into account the types of therapy
currently in use and the results of comparative analysis of the
efﬁcacy, safety, and cost-effectiveness of alternative therapies
already on the list.
In section 19, the applicant has to indicate whether the drug
may be used for other indications than the one chosen as the
main justiﬁcation for inclusion in the list (section 9 based on ICD-
10 and section 10 based on instructions for use). In other words, is
there a possibility that there will be a “leakage” of the drug for the
treatment of other medical conditions or forms of disease if it is
included in the list?
Section 20 asks the applicant to estimate the cost of treatment
with the new medication per patient per year. The cost should be
calculated for the categories listed in section 9 in accordance with
ICD-10. The source of price information, the day when calcula-
tions were performed, and the steps of cost estimation should be
provided in the ﬁeld for text comments.
Sections 21 to 23 are devoted to quantitative analysis of
patients on the regional reimbursement list for the given ICD-
10 code.
The number of patients on the regional reimbursement list for
the given ICD-10 code (section 21) is determined automatically,
thanks to an inbuilt database of regional reimbursement (region-
speciﬁc), which contains information about the number ofprescriptions for the previous year according to the statistics of
regional ministries/departments of health. Sections 22 and 23 are
concerned with “quantitative prioritization” of patients entitled
to reimbursement. The percentage and number of patients who
may be prescribed the reimbursed drug are estimated in the
former and the percentage and number of patients who should
have priority in drug supply are estimated in the latter. Once the
percentages are entered, the number of such patients is calcu-
lated automatically: in the former case (section 22) as a share of
the total number of patients entitled to reimbursement in the
region (section 21), and in the latter case (section 23) as a share of
the total number of patients entitled to reimbursement in the
region who may be prescribed the evaluated drug (section 22).
High-priority patient groups are always determined by the chief
specialist or members of the formulary commission. The appli-
cant, if this is a representative of a pharmaceutical company,
does not have enough competence or authority to make such
decisions.
In section 24, the applicant has to describe the existing
approaches to the management of patients with this disease in
the region. Two approaches are possible when ﬁlling out this
section. Either the chief specialist may provide this description or
(the more formal approach) a query may be made for the
appropriate ICD-10 code to collect data about the prescription of
drugs to patients entitled to reimbursement over the last year.
This information can be found in the automated system itself as
a separate database. If the second approach is used, it is
important to ﬁlter the results obtained from the database,
selecting from the list only those drugs that are directly relevant
to the therapy of this particular disease (have the same indica-
tions as the evaluated drug). The reason for this is that the
database search yields information about all the medications
dispensed to reimbursed patients under a particular ICD-10 code
(which often refers to symptomatic treatment, therapy for exac-
erbations or comorbidities, etc.).
In section 25, the applicant submits information about the
inclusion of the evaluated drug in Russian and foreign regula-
tions governing drug acquisition and prescription, such as the list
of vital and essential drugs, standards of medical care, national
and foreign treatment guidelines, and so on.
Section 26 of the application describes the cost of managing
patients with the medical condition for which the evaluated drug
is indicated. This section also contains a database listing the cost
of prescribed medications for different ICD-10 codes over the
last year.
Section 27 of the application discusses the possible need to
exclude or limit the use of other medications previously included
in the regional list in case the new drug is added. This section is
particularly relevant in case of regional budget deﬁcit and should
be completed by a chief specialist on the basis of a detailed
analysis of the use of medications in the framework of the
regional reimbursement scheme.
In section 28, the applicant has to estimate the cost
of including the evaluated drug in the list for prioritized reim-
bursement groups. The following formula should be used for
this calculation: the cost of treating one patient with this
medication for 1 year (s. 20)  the number of patients entitled
to reimbursement in the region who have a high priority for the
provision of this medication (s. 23)  savings due to exclusion/
limited use of other medications (s. 27). This calculation should
be repeated for all conditions (ICD-10 codes) mentioned in the
application.
Section 29 describes the need for special training of physicians
concerning the prescription of the new drug in their practice.
Overall, because the new medication will be prescribed and used
in ambulatory practice, any possible difﬁculties with dosing,
administration, special training, and so on have to be minimal.
Fig. 1 – Algorithm for evaluation of the application (dossier)
for inclusion in the regional reimbursement list.
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references in the completed application in the bibliography
(section 30). Bibliography can be arranged alphabetically or
in the order of citation and should include the author(s) of
each study (surname and initials), study/regulation title, and
publisher.
The application can be completed in several sessions. Incom-
plete applications can be saved as drafts and continued later at a
convenient time.
Before previewing and submitting the application, the system
performs a preliminary check. If the checkup is not successful,
the user is prompted to ﬁll in the incorrect or missing ﬁelds.
According to experts and representatives of the regional
ministries of health, the Dossier automated system is conven-
ient for use and allows one to make evidence-based decisions
taking fully into account all the preparation’s characteristics,
subgroup analysis results, and capacities of the local budgets. On
average, the full expert cycle of one preparation (from the
moment of the application’s submission in the system to the
formulary commission’s ﬁnal decision) takes 1.5 months. It can
take longer than that if there are mistakes in the Dossier
application form (which may lead to the return of the application
for updating) and depending on the frequency of the formulary
commissions’ meetings, which make a ﬁnal decision on listing
(in some regions, formulary commissions’ meetings take place
not more than once a quarter). Special trainings are arranged for
experts and potential applicants (trainings for experts are con-
ducted separately) before the implementation of the Dossier
system in the practical activities of the regional ministries of
health. Following completion of the theoretical section of the
training, the participants are offered to work in the system
online independently, for example, to enter application and
perform evaluation of the drug.
The number of new drugs that receive positive assessment by
experts of formulary commissions and are listed may vary
signiﬁcantly depending on the region, number, and composition
of people entitled to the regional pharmaceutical beneﬁts pro-
grams, ﬁnancial situation in the region as well as the backlog of
applications submitted for listing. For example, in the Moscow
region, the number of drugs that were included in reimburse-
ment lists during 1 year did not exceed 15 names. The total
number of submissions through the Dossier system, however,
was approximately twice as large.Algorithm of Decision Making Based on an Analysis of the
Application (Dossier) for Inclusion in the Reimbursement List
The decision to include or not to include the evaluated drug in
the list has to be reached by the chief specialist and members of
the formulary commission on the basis of a multicriteria analysis
of the data pertaining to the evaluated drug, the number of
reimbursed patients in the region, the high-priority groups to
whom the drug is indicated, the cost of therapy, and so on. Thus,
an expert making a decision has to have an intimate knowledge
of both WHAT is recommended for inclusion in the list and FOR
WHOM this drug is added to the list (as regards the number of
patients and the cost). The stages of expert evaluation of
submitted data leading to the ﬁnal decision are presented in
Fig. 1.
Adherence to this algorithm, a careful consideration of all
pros and cons of adding the drug to the list, and a stepwise
evaluation will allow us to optimize the purchase of medications,
choosing from a large number of drugs suggested for inclusion in
limited lists the most expedient in terms of both clinical and
economic characteristics and the real demands of pharmacolog-
ical therapy and the budget resources.Conclusions
The creation of the Dossier automated system is an initiative of
the Research Center for Clinical and Economic Evaluation and
Pharmacoeconomics of the N.I. Pirogov Russian State Medical
University with the support of several regional ministries and
departments of health. Today, the actual implementation of this
automated system is a unique experience of only a handful of
regions. The system, however, is ready for implementation and, if
necessary, can be adjusted for use in every federal subject of
Russia.
The advantages of setting up an automated system for the
compilation of regional lists are self-evident. For instance, we can
mention the following: a formal procedure for the completion of
the application form (dossier) and expert evaluation; a stepwise
evaluation and multidisciplinary approach; decision making
based on a comprehensive, multicriteria analysis of data on the
new drug; transparency of all decisions (every stage of the
evaluation is reﬂected in the system, including the grounds for
every decision and the time of decision); a shift to electronic
documentation, which can save time and money (the applica-
tions can be completed, evaluated, and edited online); and an
opportunity to process data on the new medication analytically,
considering pooled data on pharmacotherapeutic and Anatomi-
cal Therapeutic Chemical groups, nosological categories, and so
on. Furthermore, the system has a signiﬁcant educational com-
ponent that helps the user build a logical chain to promote the
new drug on the market and helps the chief specialist to
determine whether there is a real need to add this drug to the
list, as well as to estimate the requisite purchase size and budget
expenses.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 8 4 – 2 8 9 289If such a system was implemented in federal subjects,
this could provide standard algorithms of expert evaluation,
decision-making criteria, and requirements concerning the data
to be submitted with the application for inclusion in the lists. As
more data on different medications are accumulated in regional
automated systems, a single “databank” can be created with the
help of both experts and applicants that will include comprehen-
sive information about the efﬁcacy, safety, and economic accept-
ability of reimbursed drugs, as well as the cost and quantitative
characteristics of pharmacotherapies of various medical conditions.
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